Aberrant Expression of CD56 in Patients With Hematologic Malignancies.

Hematologic Malignancies Clinical Trial

Official title:

Resident Doctor at Clinical Pathology Department

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04546945
• Other study ID #: Asmaa Hassan
• Status: Recruiting
• Start date: July 20, 2020
• Est. completion date: December 30, 2024

Study information

• Verified date: July 2022
• Source: Assiut University
• Contact: asmaa H mohamed, R.DR
• Phone: +201024850070
• Email: a94asmaa[@]gmail.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

CD56(cluster of differentiation 56) was found to be ectopically expressed in multiple myeloma . A met analysis indicated that CD56 over expression may be an adverse prognostic factor in AML. To the best of our knowledge, no available data the expression pattern of CD56 in other Hematologic malignancies. This work is designed to evaluate the expression pattern of CD56 in hematologic malignancies.

Description:

CD56 is the archetypal phenotypic marker of natural killer cells but can actually be expressed by many more immune cells, including alpha, beta T cells, gamma, delta T cells, dendritic cells, and monocytes. Common to all these CD56 expressing cell types have strong immunostimulatory effector functions, including T helper 1 cytokine production and an efficient cytotoxic capacity. Interestingly, both numerical , functional deficiencies and phenotypic alterations of the CD56 immune cell fraction have been reported in patients with various infectious, autoimmune, or malignant diseases.CD56 is also known as neural cell adhesion molecule (NCAM).

Hematologic malignancies are a heterogeneous group of diseases of diverse incidence, prognosis and etiology that arise from malignant transformation of cells from the bone marrow or the lymphatic system.There are two major groups of Hematologic malignancies according to their cell lineage: Myeloid and lymphoid. Lymphoid neoplasms are a varied group that includes non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), leukemia and multiple myeloma (MM).myeloid neoplasms and acute leukaemia include: Myeloproliferative neoplasms (MPN), Myelodysplastic/myeloproliferative neoplasms (MDS/MPN), Myelodysplastic syndromes (MDS), Acute myeloid leukaemia (AML), Acute leukemias of ambiguous lineage, B-lymphoblastic leukaemia/lymphoma, T-lymphoblastic leukaemia/lymphoma.The exact causes of Hematologic malignancies are still unknown although multiple epidemiological studies have reported an association between the development of Hematologic malignancies and several risk factors. Some factors are well documented to increase the risk of some types of leukaemia such as benzene exposure and ionizing radiation.However, many other factors were observed to have an association with Hematologic malignancies such as age, gender, tobacco smoking , obesity , hepatitis C virus (HCV) infection , family history , and environmental exposure to pesticides but with no clear evidence.

CD56 was found to be ectopically expressed in multiple myeloma. A met analysis indicated that CD56 over expression may be an adverse prognostic factor in AML. To the best of our knowledge, no available data the expression pattern of CD56 in other Hematologic malignancies. This work is designed to evaluate the expression pattern of CD56 in hematologic malignancies.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 38
• Est. completion date: December 30, 2024
• Est. primary completion date: December 30, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients with hematologic malignancies.

• Newly diagnosed

Exclusion Criteria:

• Patients with hematologic disorders other than hematologic malignancies.

Related Conditions & MeSH terms

• Hematologic Malignancies
• Hematologic Neoplasms
• Neoplasms

Intervention

Diagnostic Test:
• CD56
detection of CD56 by flow cytometry

Locations

Country	Name	City	State
Egypt	Assiut University	Assiut
Egypt	Assiut university	Assiut

Sponsors (1)

Lead Sponsor	Collaborator
Asmaa Hassan mohamed Abdel Mawjoud

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To identify the Pattern of expression of CD56 in hematologic malignancies.	Expression of aberrant CD56 in hematologic malignancies by flowcytometry. To explore incidence of Expression of aberrant CD56 in hematologic malignancies .; Correlation between this expression and outcome of the patient.	1 years

External Links

•   (1) Kelly-Rogers J, Madrigal-Estebas L, O'Connor T, Doherty DG. Activation-induced expression of CD56 by T cells is associated with a reprogramming of cytolytic activity and cytokine secretion profile in vitro. Hum Immunol (2006)
•   (10) A. Arber, Attilio Orazi,Hasserjian, J ¨urgen Thiele,J. Borowitz,Le Beau, D. Bloomfield, Cazzola, and W. Vardiman : The 2016 revision to the World Health Organization classification of myeloid neo
•   (11) Rodriguez-Abreu D, Bordoni A, Zucca E. Epidemiology of hematological malignancies. Ann Oncol 2007.
•   (12) Floderus B, Persson T, Stenlund C, Wennberg A, Ost A, Knave B. Occupational exposure to electromagnetic fields in relation to leukemia and brain tumors: a case-control study in Sweden. Cancer Causes Control 1993
•   (13) Kedia S, Bhatt VR, Rajan SK, Tandra PK, El Behery RA, Akhtari M. Benign and malignant hematological manifestations of chronic hepatitis C virus infection. Int J Prev Med 2014.
•   (14) Pan Y, Wang H, Tao Q, Zhang C, Yang D, Qin H, et al. Absence of both CD56 and CD117 expression on malignant plasma cells is related with a poor prognosis in patients with newly diagnosed multiple myeloma. Leuk Res (2016)
•   (15) Xu S, Li X, Zhang J, Chen J. Prognostic value of CD56 in patients with acute myeloid leukemia: a meta-analysis. J Cancer Res Clin Oncol (2015)
•   (16) Hazra A. Using the confidence interval confidently. J Thorac Dis 2017.
•   (3) Van Acker HH, Anguille S, Willemen Y, Van den Bergh JM, Berneman ZN, Lion E, et al. Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells. J Hematol Oncol (2016)
•   (5) Flowers CR, Glover R, Lonial S and Brawley OW: Racial differences in the incidence and outcomes for patients with hematological malignancies. Curr Probl Cancer.
•   (6) Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, Marcos-Gragera R, Maynadie M, Simonetti A, Lutz JM, et al: Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project. Blood.
•   (7) Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H and Jaffe ES: The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications. Blood.
•   (8)Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A and Bloomfield CD: The 2008 revision of the World Health Organization (WHO)
•   (9) Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD and Jaffe ES: The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood.
•   Heleen H. Van Acker,* Anna Capsomidis, Evelien L. Smits, and Viggo F. Van Tendeloo ( CD56 in the Immune System: More Than a Marker for Cytotoxicity?) Published 2017 frontiers in immunology.
•   Roothans D, Smits E, Lion E, Tel J, Anguille S. CD56 marks human dendritic cell subsets with cytotoxic potential. Oncoimmunology (2013)